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Abstract
Background: Palbociclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6. In the
randomized, open-label, phase II PALOMA-1/TRIO-18 trial, palbociclib in combination with letrozole improved
progression-free survival (PFS) compared with letrozole alone as first-line treatment of estrogen receptor (ER)
-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer (20.2 months
versus 10.2 months; hazard ratio (HR) = 0.488, 95 % confidence interval (CI) 0.319–0.748; one-sided p = 0.0004).
Grade 3–4 neutropenia was the most common adverse event (AE) in the palbociclib + letrozole arm. We now
present efficacy and safety analyses based on several specific patient and tumor characteristics, and present in
detail the clinical patterns of neutropenia observed in the palbociclib + letrozole arm of the overall safety
population.
Methods: Postmenopausal women (n = 165) with ER+, HER2-negative, advanced breast cancer who had not
received any systemic treatment for their advanced disease were randomized 1:1 to receive either palbociclib
in combination with letrozole or letrozole alone. Treatment continued until disease progression, unacceptable
toxicity, consent withdrawal, or death. The primary endpoint was PFS. We now analyze the difference in PFS
for the treatment populations by subgroups, including age, histological type, history of prior neoadjuvant/adjuvant
systemic treatment, and sites of distant metastasis, using the Kaplan-Meier method. HR and 95 % CI are derived from a
Cox proportional hazards regression model.
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Results: A clinically meaningful improvement in median PFS and clinical benefit response (CBR) rate was seen with
palbociclib + letrozole in every subgroup evaluated. Grade 3–4 neutropenia was the most common AE with
palbociclib + letrozole in all subgroups. Analysis of the frequency of neutropenia by grade during the first six cycles of
treatment showed that there was a downward trend in Grade 3–4 neutropenia over time. Among those who
experienced Grade 3–4 neutropenia, 71.7 % had no overlapping infections of any grade and none had overlapping
Grade 3–4 infections.
Conclusion: The magnitude of clinical benefit seen with the addition of palbociclib to letrozole in improving both
median PFS and CBR rate is consistent in nearly all subgroups analyzed, and consistent with that seen in the overall
study population. The safety profile of the combination treatment in all subgroups was also comparable to that in the
overall safety population of the study.
Keywords: Breast cancer, Estrogen receptor-positive, HER2-negative, Cyclin-dependent kinase, Neutropenia
Abbreviations: AE, adverse event; CBR, clinical benefit response; CDK, cyclin-dependent kinase; CI, confidence interval;
ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; FISH, fluorescent in-situ hybridization; HER2, human
epidermal growth factor receptor 2; HR, hazard ratio; HR+, hormone receptor-positive; ITT, intention-to-treat; PFS,
progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors
Background
Cyclin-dependent kinases (CDKs) are a large family of
serine-threonine kinases that play several critical roles in
cell cycle regulation. They are an attractive therapeutic
target given that alterations in cell cycle genes have been
implicated in breast cancer as well as multiple other ma-
lignancies. Palbociclib (PD-0332991) is a first-in-class,
orally active, selective, reversible inhibitor of CDK 4 and
6 [1]. Pre-clinical studies have demonstrated the activity
of palbociclib in blocking growth of estrogen receptor
(ER)-positive luminal cell lines alone and in combination
with anti-estrogens [2]. Clinical data have recently estab-
lished palbociclib as a novel therapeutic option for
women with ER+, human epidermal growth factor re-
ceptor 2 (HER2)-negative, advanced breast cancer [3–5].
In the randomized, open-label, phase II PALOMA-1/
TRIO-18 trial, the safety and efficacy of palbociclib in
combination with the aromatase inhibitor letrozole was
compared with letrozole alone as first-line treatment of
women with ER-positive, HER2-negative (ER+/HER2–),
advanced breast cancer [3]. A total of 165 postmeno-
pausal women with ER+/HER2– advanced breast cancer
who had not received any treatment for their advanced
disease were randomized (1:1), 84 to palbociclib plus
letrozole and 81 to letrozole alone. The study stratified
patients by disease site and disease-free interval. The
primary endpoint was investigator-assessed progression-
free survival (PFS). At the time of the data cut-off for
the final analysis (29 November 2013), median follow-
up was 29.6 months (95 % confidence interval (CI)
27.9–36.0) for the palbociclib plus letrozole arm and
27.9 months (95 % CI 25.5–31.1) for the letrozole
arm [3]. Median PFS in the intention-to-treat (ITT)
population was 20.2 months (95 % CI 13.8–27.5) for
the palbociclib plus letrozole arm and 10.2 months
(95 % CI 5.7–12.6) for the letrozole arm (hazard ratio
(HR) = 0.488, 95 % CI 0.319–0.748; one-sided p = 0.0004)
[3]. The clinical benefit response (CBR) rate (complete re-
sponse + partial response + stable disease ≥24 weeks) for
the ITT population was 81 % in the palbociclib plus letro-
zole arm and 58 % in the letrozole arm [3]. Overall sur-
vival data were not mature at the time of the data cut-off.
Grade 3 neutropenia was the most common adverse effect
in the palbociclib plus letrozole arm (48 % versus 1 % in
the letrozole alone arm) [3]. On the basis of these data,
palbociclib (Ibrance®, Pfizer) was granted accelerated ap-
proval by the US Food and Drug Administration (FDA) in
February 2015, in combination with letrozole as initial
endocrine-based therapy for postmenopausal women with
ER+/HER2– metastatic breast cancer [6].
Despite the high incidence of neutropenia in the pal-
bociclib plus letrozole arm of the PALOMA-1/TRIO-18
trial, there were no reported cases of febrile neutropenia
or neutropenia-related infections. This is in contrast to
cytotoxic chemotherapy where neutropenia is not only a
common dose-limiting toxicity but is also associated with
serious infections and infection-related morbidity [7, 8].
Ensuing complications can result in hospitalization, high
treatment costs, and increased mortality [9–11].
There are two objectives in the current study: 1) to
perform an expanded analysis of the efficacy (PFS and
CBR) and safety of palbociclib plus letrozole in clinically
relevant subgroups from the PALOMA-1/TRIO-18 trial
including age <65 years or ≥65 years, pathologic type
(ductal versus lobular carcinoma), effect of prior neoad-
juvant/adjuvant systemic treatment, and metastasis in
bone only, visceral sites, or other sites (i.e., soft-tissue,
nodes, and so forth); and 2) to further delineate clinical
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patterns of neutropenia associated with palbociclib in
the PALOMA-1/TRIO-18 trial in order to aid clinicians
in the management of palbociclib-induced neutropenia.
Methods
Study design
The PALOMA-1/TRIO-18 trial was an international,
phase II, multicenter, open-label, randomized study. De-
tails of the study have been reported previously [3]. In
brief, postmenopausal women with ER+/HER2– advanced
breast cancer were enrolled in two cohorts that accrued
sequentially. Patients in both cohorts 1 and 2 were
required to have advanced breast cancers defined as
ER-positive determined by immunohistochemistry, and
HER2-negative determined either by fluorescent in-situ
hybridization (FISH) or immunohistochemistry in local
laboratory testing. Patients in cohort 2 were additionally
required to have cancers with amplification of cyclin D1
(CCND1), loss of p16 (INK4A or CDKN2A), or both, as
determined in central laboratory testing. Amplification of
CCND1 and loss of p16 were determined by a four-color
FISH assay as previously described [3]. Patients in both
cohorts were randomized 1:1 to receive palbociclib plus
letrozole or letrozole alone and were stratified by dis-
ease site (bone-only, visceral, other) and disease-free
interval (>12 months from completion of adjuvant
treatment to disease recurrence versus ≤12 months or
de novo advanced disease). For the final analysis of the
primary endpoint, a combined analysis of cohorts 1 and
2 was performed [3].
All patients provided informed consent before any
study-specific screening procedures were performed.
The study was conducted in accordance with the
International Conference on Harmonization and guide-
lines on Good Clinical Practice and was approved by the
institutional review boards of the participating centers.
The study is registered with the ClinicalTrials.gov, number
NCT00721409.
Patients
Postmenopausal women (≥18 years) with ER+/HER2–
advanced breast cancer with evidence of 1) locally re-
current disease not amenable to resection or radiation
therapy with curative intent or 2) metastatic disease
were eligible. Additional key inclusion criteria included
measurable disease by Response Evaluation Criteria in
Solid Tumors (RECIST, version 1.0) or bone-only dis-
ease, an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1, and adequate organ (bone
marrow, renal, and hepatic) function. Key exclusion cri-
teria included previous treatment for advanced breast
cancer, prior neoadjuvant treatment with letrozole with
disease recurrence ≤12 months, previous treatment
with a CDK inhibitor, or presence of brain metastasis.
Study treatment
Patients randomized to the palbociclib plus letrozole
arm (n = 84) received oral palbociclib 125 mg once daily
for 3 weeks followed by 1 week off in 28-day cycles plus
oral letrozole 2.5 mg once daily. Patients randomized to the
letrozole arm (n = 81) received oral letrozole 2.5 mg once
daily. Study treatment continued until disease progression,
unacceptable toxicity, consent withdrawal, or death.
Endpoints and assessments
The primary endpoint was investigator-assessed PFS, de-
fined as the time from randomization to objective disease
progression or death on study. Secondary efficacy end-
points were objective response (by RECIST version 1.0),
CBR, duration of response, and overall survival (OS).
Additional secondary endpoints were safety, tissue/serum
biomarker analyses, and patient-reported outcomes.
Tumor assessments of the chest, abdomen, and pelvis
were performed by computed tomography or magnetic
resonance imaging and clinical assessment of superficial
disease (if applicable) at screening and every 8 weeks
thereafter. Bone lesions (when applicable) were assessed
by radiography; bone scans were performed at baseline
and every 12 weeks. Safety was monitored throughout
the study and adverse events (AEs) were graded accord-
ing to the National Cancer Institute Common Termin-
ology Criteria for Adverse Events (CTCAE) version 3.0.
Hematology and blood chemistry assessments were done
every 2 weeks for the first two treatment cycles and at
the beginning of each subsequent cycle. Dosing modifi-
cations were performed as described in Additional file 1
(Table S1). Primary prophylactic use of granulocyte
colony-stimulating factors was not permitted, although
these were allowed to treat treatment-emergent neutro-
penia as indicated by current ASCO guidelines. Erythro-
poietin was permitted at the investigator’s discretion for
the supportive treatment of anemia.
Statistical analysis
Statistical analysis of the overall study population was previ-
ously described in detail [3]. All efficacy analyses were per-
formed on the ITT population; safety analyses included all
patients who had received at least one dose of the study
treatment. PFS was assessed using the Kaplan-Meier
method; HR and 95 % CI were derived from a Cox propor-
tional hazards regression model. No adjustments were
made for multiple comparisons in the subgroup analyses
since they are considered exploratory analyses. All statistical
analyses were performed with SAS version 9.2 or later.
Results
Subgroup analyses: baseline characteristics
The baseline characteristics of the subgroups are summa-
rized in Table 1. In the ITT population (n = 165), 54 % of
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Table 1 Baseline characteristics of subgroups (intention-to-treat population)
Age group <65 years (n = 89) ≥65 years (n = 76)
P+ L (n = 47) L (n = 42) P + L (n = 37) L (n = 39)
Median age (range), years 55.0 (41–64) 56.5 (38–64) 72.0 (65–89) 70.0 (65–84)
ECOG performance status
0 26 (55.3 %) 23 (54.8 %) 20 (54.1 %) 22 (56.4 %)
1 21 (44.7 %) 19 (45.2 %) 17 (45.9 %) 17 (43.6 %)
Disease stage
IIIB 1 (2.1 %) 1 (2.4 %) 1 (2.7 %) 0
IV 46 (97.9 %) 41 (97.6 %) 36 (97.3 %) 39 (100.0 %)
Disease sitea
Bone-only 9 (19.2 %) 3 (7.1 %) 8 (21.6 %) 9 (23.1 %)
Visceral 19 (40.4 %) 22 (52.4 %) 18 (48.7 %) 21 (53.9 %)
Other 19 (40.4 %) 17 (40.5 %) 11 (29.7 %) 9 (23.1 %)
Prior systemic treatment
None 24 (51.1 %) 23 (54.8 %) 20 (54.1 %) 14 (35.9 %)
Yes 23 (48.9 %) 19 (45.2 %) 17 (45.9 %) 25 (64.1 %)
Histological type Ductal carcinoma (n = 117) Lobular carcinoma (n = 37)
P+ L (n = 63) L (n = 54) P + L (n = 18) L (n = 19)
Median age (range), years 63 (41–89) 65 (42–84) 60 (50–74) 62 (38–78)
ECOG performance status
0 36 (57.1 %) 29 (53.7 %) 9 (50.0 %) 14 (73.7 %)
1 27 (42.9 %) 25 (46.3 %) 9 (50.0 %) 5 (26.3 %)
Disease stage
IIIB 2 (3.2 %) 1 (1.9 %) 0 0
IV 61 (96.8 %) 53 (98.1 %) 18 (100.0 %) 19 (100.0 %)
Disease sitea
Bone-only 11 (17.5 %) 8 (14.8 %) 4(22.2 %) 3 (15.8 %)
Visceral 28 (44.4 %) 30 (55.6 %) 8 (44.4 %) 7 (36.8 %)
Other 24 (38.1 %) 16 (29.6 %) 6 (33.3 %) 9 (47.4 %)
Prior systemic treatment
None 36 (57.1 %) 26 (48.1 %) 6 (33.3 %) 7 (36.8 %)
Yes 27 (42.9 %) 28 (51.9 %) 12 (66.7 %) 12 (63.2 %)
Prior systemic treatment None (n = 81) Yes (n = 84)
P+ L (n = 44) L (n = 37) P + L (n = 40) L (n = 44)
Median age (range), years 63.0 (41–83) 62.0 (43–76) 60.0 (46–89) 65.5 (38–84)
ECOG performance status
0 26 (59.1 %) 18 (48.6 %) 20 (50.0 %) 27 (61.4 %)
1 18 (40.9 %) 19 (51.4 %) 20 (50.0 %) 17 (38.6 %)
Disease stage
IIIB 1 (2.3 %) 0 1 (2.5 %) 1 (2.3 %)
IV 43 (97.7 %) 37 (100.0 %) 39 (97.5 %) 43 (97.7 %)
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patients were <65 years of age. The majority (71 %) of pa-
tients had ductal carcinoma and 22.4 % had lobular car-
cinoma (the remaining 6.6 % of patients had mixed
histology, tubular, or mucinous types). Approximately half
(49 %) of the patients had not received prior neoadjuvant
or adjuvant systemic treatment. Twenty-nine (17.6 %) pa-
tients had bone-only disease at baseline, 48.5 % of patients
had visceral metastases (lung and/or liver ± any other site),
and 33.9 % of patients had other metastases (bone with
other non-visceral sites or other disease sites alone). In
the subgroup that had visceral metastases, 52.5 % had me-
tastases in the liver and 76 % had metastases in the lungs;
further details on the baseline characteristics of the pa-
tients within this subgroup are summarized in Additional
file 1 (Table S2). In general, baseline clinical characteristics
in the palbociclib plus letrozole arm and letrozole alone
arm were well balanced within each subgroup (Table 1),
although there were slight imbalances in disease site and
prior systemic treatment.
Subgroup analyses: efficacy
The median PFS and the CBR rate for the subgroups are
summarized in Table 2; Kaplan-Meier plots of PFS for
the subgroups were determined (Figs. 1 and 2).
Palbociclib plus letrozole improved median PFS in
both subgroups of age. In patients <65 years of age,
median PFS was 18.8 months (95 % CI 12.8–26.1)
with palbociclib plus letrozole and 7.7 months (95 % CI
2.8–10.9) with letrozole alone (HR = 0.315, 95 % CI
0.184–0.539; p < 0.00001). In patients ≥65 years of age,
median PFS was 26.2 months (95 % CI 12.6 to not
estimable) with palbociclib plus letrozole and 12.9 months
(95 % CI 5.7–22.2) with letrozole alone (HR = 0.505,
95 % CI 0.269–0.948; p = 0.0155).
Palbociclib plus letrozole improved median PFS in pa-
tients with ductal carcinoma as well as in patients with
lobular carcinoma. Median PFS in the ductal population
was 24.4 months (95 % CI 13.1–35.3) with palbociclib
plus letrozole and 11.1 months (95 % CI 7.3–13.3)
with letrozole alone (HR = 0.393, 95 % CI 0.239–0.647;
p = 0.00007). The subgroup with lobular carcinoma
was limited by the small patient numbers in each arm
(n = 18 in the palbociclib plus letrozole arm; n = 19 in the
letrozole alone arm). Median PFS in this subgroup was
9.4 months (95 % CI 7.8–18.8) with palbociclib plus letro-
zole and 4.8 months (95 % CI 1.9–16.4) with letrozole
alone (HR = 0.626, 95 % CI 0.282–1.391; p = 0.123).
Palbociclib plus letrozole improved median PFS regard-
less of whether patients had received prior neoadjuvant/
adjuvant systemic treatment. Median PFS in patients with-
out prior neoadjuvant/adjuvant systemic treatment was
24.4 months (95 % CI 13.1–35.3) with palbociclib plus
letrozole and 8.2 months (95 % CI 5.7–12.5) with letrozole
alone (HR = 0.341, 95 % CI 0.194–0.599; p = 0.00004). Me-
dian PFS in patients with prior systemic treatment was
16.1 months (95 % CI 11 to not estimable) with palboci-
clib plus letrozole and 10.9 months (95 % CI 3.5–16.6)
with letrozole alone (HR = 0.539, 95 % CI 0.302–
0.962; p = 0.0169). Within the subgroup that had prior
systemic treatment, 65.5 % of patients had prior anti-
hormone treatment. Median PFS in patients with
prior anti-hormone treatment was 18.8 months (95 % CI
Table 1 Baseline characteristics of subgroups (intention-to-treat population) (Continued)
Disease sitea
Bone-only 6 (13.6 %) 5 (13.5 %) 11 (27.5 %) 7 (15.9 %)
Visceral 24 (54.6 %) 19 (51.4 %) 13 (32.5 %) 24 (54.6 %)
Other 14 (31.8 %) 13 (35.1 %) 16 (40.0 %) 13 (29.6 %)
Disease sitea Bone-only (n = 29) Visceral (n = 80) Other (n = 56)
P + L (n = 17) L (n = 12) P + L (n = 37) L (n = 43) P + L (n = 30) L (n = 26)
Median age (range), years 63.0 (46–89) 69.0 (42–73) 63.0 (41–83) 64.0 (38–84) 62.0 (52–78) 62.0 (43–75)
ECOG performance status
0 11 (64.7 %) 10 (83.3 %) 19 (51.4 %) 19 (44.2 %) 16 (53.3 %) 16 (61.5 %)
1 6 (35.3 %) 2 (16.7 %) 18 (48.6 %) 24 (55.8 %) 14 (46.7 %) 10 (38.5 %)
Disease stage
IIIB 0 0 0 0 2 (6.7 %) 1 (3.8 %)
IV 17 (100.0 %) 12 (100.0 %) 37 (100.0 %) 43 (100.0 %) 28 (93.3) 25 (96.2)
Prior systemic treatment
None 6 (35.3 %) 5 (41.7 %) 24 (64.9 %) 19 (44.2 %) 14 (46.7 %) 13 (50.0 %)
Yes 11 (64.7 %) 7 (58.3 %) 13 (35.1 %) 24 (55.8 %) 16 (53.3 %) 13 (50.0 %)
Data are n (%) unless otherwise indicated
aBased on case report form data
ECOG Eastern Cooperative Oncology Group, L letrozole alone, P + L palbociclib + letrozole
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9.7 to not estimable) with palbociclib plus letrozole and
12.9 months (95 % CI 2.1–21.8) with letrozole alone
(HR = 0.460, 95 % CI 0.222–0.956; p = 0.0165).
The subgroup of patients with bone-only disease was lim-
ited by a small number of patients in each arm (n = 17 in
the palbociclib plus letrozole arm; n = 12 in the letrozole
alone arm). Despite this, palbociclib plus letrozole improved
the median PFS compared with letrozole alone (Table 2).
Median PFS in patients with either visceral metastases or
distant metastases at other sites was higher with palbociclib
plus letrozole than with letrozole alone (Table 2).
Palbociclib plus letrozole improved the CBR rate in all
subgroups compared with letrozole alone (Table 2); the
difference in the CBR rate with the combination treat-
ment for each subgroup was consistent with that seen
for the overall study population.
Subgroup analyses: safety
The safety analyses on the subgroups are summarized in
Table 3. The most common all-cause AEs that occurred
in at least 10 % of patients in the palbociclib plus letrozole
arm of the safety population for each subgroup are sum-
marized in detail in Additional file 1 (Tables S3–S11).
All subgroups had a higher incidence of Grade 3–4
AEs in the palbociclib plus letrozole arm than in the
letrozole arm (≤88.2 % versus ≤32.4 %) (Table 3). There
was one Grade 5 AE in the palbociclib plus letrozole
arm: the event was death due to disease progression in a
patient <65 years of age with lobular carcinoma and dis-
tant metastases at visceral sites who had not received
prior systemic treatment.
Neutropenia, leukopenia, fatigue, and anemia were the
most common AEs in all subgroups in the palbociclib
plus letrozole study arm (Table 3). The incidence of all-
causality Grade 3–4 AEs with palbociclib plus letrozole
was generally similar in all subgroups, and so was the in-
cidence of all-causality serious adverse events (SAEs)
with the combination treatment.
The percentage of patients who had treatment discon-
tinuations due to all-causality AEs with palbociclib plus
Table 2 Progression-free survival (PFS) and clinical benefit response (CBR) rate of subgroups (intention-to-treat population)
Age group <65 years (n = 89) ≥65 years (n = 76)
P+ L (n = 47) L (n = 42) P + L (n = 37) L (n = 39)
Median PFS (95 % CI), months 18.8 (12.8–26.1) 7.7 (2.8–10.9) 26.2 (12.6–NE) 12.9 (5.7–22.2)
HR (95 % CI) 0.315 (0.184–0.539) 0.505 (0.269–0.948)
CBR* rate (95 % CI), % 80.9 (66.7–90.9) 54.8 (38.7–70.2) 81.1 (64.8–92.0) 61.5 (44.6–76.6)
Histological type Ductal carcinoma (n = 117) Lobular carcinoma (n = 37)
P+ L (n = 63) L (n = 54) P + L (n = 18) L (n = 19)
Median PFS (95 % CI), months 24.4 (13.1–35.3) 11.1 (7.3–13.3) 9.4 (7.8–18.8) 4.8 (1.9–16.4)
HR (95 % CI) 0.393 (0.239–0.647) 0.626 (0.282–1.391)
CBR* rate (95 % CI), % 82.5 (70.9–90.9) 63.0 (48.7–75.7) 72.2 (46.5–90.3) 42.1 (20.3–66.5)
Prior systemic treatment None (n = 81) Yes (n = 84)
P + L (n = 44) L (n = 37) P + L (n = 40) L (n = 44)
Median PFS (95 % CI), months 24.4 (13.1–35.3) 8.2 (5.7–12.5) 16.1 (11–NE) 10.9 (3.5–16.6)
HR (95 % CI) 0.341 (0.194–0.599) 0.539 (0.302–0.962)
CBR* rate (95 % CI), % 84.1 (69.9–93.4) 70.3 (53.0–84.1) 77.5 (61.5–89.2) 47.7 (32.5–63.3)
Prior anti-hormone treatment (n = 55)
P + L (n = 27) L (n = 28)
Median PFS (95 % CI), months NA 18.8 (9.7–NE) 12.9 (2.1–21.8)
HR (95 % CI) NA 0.460 (0.222–0.956)
CBR* rate (95 % CI), % NA 77.8 (57.7–91.4) 53.6 (33.9–72.5)
Disease sitea Bone-only (n = 29) Visceral (n = 80) Other (n = 56)
P + L (n = 17) L (n = 12) P + L (n = 37) L (n = 43) P + L (n = 30) L (n = 26)
Median PFS (95 % CI), months NE (9.4–NE) 13.3 (1.8–NE) 12.8 (9.7–17.2) 7.4 (3.7–11.1) 24.4 (18.1–35.3) 11.2 (3.5–16.4)
HR (95 % CI) 0.294 (0.092–0.945) 0.547 (0.317–0.944) 0.402 (0.200–0.808)
CBR* rate (95 % CI), % 88.2 (63.6–98.5) 58.3 (27.7–84.8) 75.5 (58.5–88.2) 60.5 (44.4–75.0) 83.3 (65.3–94.4) 53.8 (33.4–73.4)
*The CBR was determined by investigator assessment
aBased on case report form data
CI confidence interval, HR hazard ratio, L letrozole alone, NA not applicable, NE not estimable, P + L palbociclib + letrozole
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Fig. 1 Progression-free survival (intention-to-treat population) in subgroups based on age, histological type of breast cancer, and history of prior
neoadjuvant/adjuvant systemic treatment. CI confidence interval, LET letrozole
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Fig. 2 Progression-free survival (intention-to-treat population) in subgroups based by distant metastases. CI confidence interval, LET letrozole
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letrozole was generally similar for all subgroups (Table 3).
A similar trend was seen with the percentage of patients
who had dose reductions due to all-causality AEs with
palbociclib plus letrozole.
Clinical patterns of neutropenia associated with palbociclib
Neutropenia was the most common AE in the palboci-
clib plus letrozole arm of the overall safety population of
the study [3]. The key findings from the clinical patterns
of neutropenia observed with palbociclib in the overall
safety population are summarized in Table 4.
In the palbociclib plus letrozole arm, 75.9 % of patients
had any grade neutropenia, 49.4 % had Grade 3 neutro-
penia, and 6.0 % had Grade 4 neutropenia (Table 4). In
contrast, in the letrozole alone arm, 5.2 % of patients
had any grade neutropenia, 1.3 % had Grade 3 neutro-
penia and no patient had Grade 4 neutropenia. The in-
vestigator-reported neutropenia AEs generally reflected
Table 3 Safety analysis of subgroups (as treated population)
Age group <65 years (n = 86) ≥65 years (n = 74)
P+ L (n = 46) L (n = 40) P + L (n = 37) L (n = 37)
AEs (all causality), n (%) 46 (100.0 %) 33 (82.5 %) 37 (100.0 %) 32 (86.5 %)
Grade 3–4 AEs (all causality), n (%) 37 (80.4 %) 4 (10.0 %) 27 (73.0 %) 12 (32.4 %)
5 most common AEs that had a higher (>10 %) incidence
in the P + L arm than in the L arm
Neutropenia, leukopenia, fatigue,
anemia, alopecia
Neutropenia, leukopenia, fatigue, anemia, nausea
SAEs (all causality), n (%) 7 (15.2 %) 1 (2.5 %) 11 (29.7 %) 4 (10.8 %)
Permanent discontinuation due to AEs (all causality), n (%) 6 (13.0 %) 1 (2.5 %) 6 (16.2 %) 1 (2.7 %)
Dose reductions due to AEs (all causality), n (%) 18 (39.1 %) NA 14 (37.8 %) NA
Histological type Ductal carcinoma (n = 113) Lobular carcinoma (n = 36)
P+ L (n = 62) L (n = 51) P + L (n = 18) L (n = 18)
AEs (all causality), n (%) 62 (100.0 %) 44 (86.3 %) 18 (100.0 %) 13 (72.2 %)
Grade 3–4 AEs (all causality), n (%) 47 (75.8 %) 13 (25.5 %) 14 (77.8 %) 2 (11.1 %)
5 most common AEs that had a higher (>10 %) incidence
in the P + L arm than in the L arm
Neutropenia, fatigue, leukopenia,
anemia, nausea
Neutropenia, anemia, leukopenia, asthenia, alopecia
SAEs (all causality), n (%) 12 (19.4 %) 5 (9.8 %) 4 (22.2 %) 0
Permanent discontinuation due to AEs (all causality), n (%) 8 (12.9 %) 1 (2.0 %) 4 (22.2 %) 1 (5.6 %)
Dose reductions due to AEs (all causality), n (%) 27 (43.5 %) NA 5 (27.8 %) NA
Prior systemic treatment None (n = 80) Yes (n = 80)
P+ L (n = 43) L (n = 37) P + L (n = 40) L (n = 40)
AEs (all causality), n (%) 43 (100.0 %) 32 (86.5 %) 40 (100.0 %) 33 (82.5 %)
Grade 3–4 AEs (all causality), n (%) 30 (69.8 %) 5 (13.5 %) 34 (85.0 %) 11 (27.5 %)
5 most common AEs that had a higher (>10 %) incidence
in the P + L arm than in the L arm
Neutropenia, fatigue, leukopenia,
anemia, alopecia
Neutropenia, leukopenia, anemia, nausea,
thrombocytopenia
SAEs (all causality), n (%) 7 (16.3 %) 2 (5.4 %) 11 (27.5 %) 3 (7.5 %)
Permanent discontinuation due to AEs (all causality), n (%) 7 (16.3 %) 1 (2.7 %) 5 (12.5 %) 1 (2.5 %)
Dose reductions due to AEs (all causality), n (%) 17 (39.5 %) NA 15 (37.5 %) NA
Disease sitea Bone-only (n = 28) Visceral (n = 80) Other (n = 52)
P + L (n = 17) L (n = 11) P + L (n = 37) L (n = 43) P + L (n = 29) L (n = 23)
AEs (all causality), n (%) 17 (100.0 %) 10 (90.9 %) 37 100.0 %) 36 (83.7 %) 29 (100.0 %) 19 (82.6 %)
Grade 3–4 AEs (all causality), n (%) 15 (88.2 %) 2 (18.2 %) 27 (73.0 %) 12 (27.9 %) 22 (75.8 %) 2 (8.7 %)
5 most common AEs that had a higher (>10 %) incidence







anemia fatigue, hot flush
SAEs (all causality), n (%) 4 (23.5 %) 1 (9.1 %) 10 (27.0 %) 3 (7.0 %) 4 (13.8 %) 1 (4.3 %)
Permanent discontinuation due to AEs (all causality), n (%) 2 (11.8 %) 0 7 (18.9 %) 1 (2.3 %) 3 (10.3 %) 1 (4.3 %)
Dose reductions due to AEs (all causality), n (%) 5 (29.4 %) NA 14 (37.8 %) NA 13 (44.8 %) NA
aBased on case report form data
AE adverse event, L letrozole alone, NA not applicable, P + L palbociclib + letrozole, SAE serious adverse event
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neutrophil laboratory findings (Table 4). Approxi-
mately half (53 %) of the patients in the palbociclib
plus letrozole arm had ≥3 episodes of neutropenia.
The median time from first dose to first episode of
any grade neutropenia in the palbociclib plus letrozole
arm was 20 days. The median duration of Grade ≥3
neutropenia was 8 days and the median duration of
Grade 4 neutropenia was 7 days. Approximately half
(51.8 %) of the patients who had any grade neutro-
penia had dose reductions, dose interruptions, or
cycle delays in the palbociclib plus letrozole arm but
only five patients (6 %) were required to permanently
discontinue treatment due to Grade 3–4 neutropenia
as per protocol. When the frequency of neutropenia
by grade during the first six cycles of treatment was
analyzed (Fig. 3a), there was a downward trend in
Grade 3–4 neutropenia over time, suggesting that
there was no cumulative toxicity and that early dose
modifications were likely effective in reducing the fre-
quency of these events.
Since neutropenia usually increases the risk for in-
fection, we explored the frequency of neutropenia
with overlapping infections in the palbociclib plus
letrozole arm. Only one patient with any grade neu-
tropenia had an overlapping Grade 3–4 infection
(Grade 3 influenza) in the palbociclib plus letrozole
arm (Table 4). The majority (71.7 %) of patients with
Grade 3–4 neutropenia in the palbociclib plus letro-
zole arm had no overlapping infections of any grade,
and those that did had grade 1–2 infections only.
When evaluating the first six cycles of treatment,
there was no clear association between the frequency
of Grade 3–4 neutropenia and all Grade infections
(Fig. 3b). Furthermore, no patients with Grade 3–4
neutropenia had overlapping Grade 3–4 infections in
the palbociclib plus letrozole arm (Table 4), nor were
there any cases of febrile neutropenia in the study.
Table 4 Neutropenia clinical patterns in the overall safety







Patients with neutropenia*, n (%)a
All Grades 63 (75.9 %) 4 (5.2 %)
Grade 3 41 (49.4 %) 1 (1.3 %)
Grade 4 5 (6.0 %) 0
Laboratory abnormality: neutrophils, n (%)‡
All Grades 77 (93.9 %) 13 (16.9 %)
Grade 3 47 (57.3 %) 2 (2.6 %)
Grade 4 4 (4.9 %) 0
Neutropenia episodes per patient, n (%)a
1 10 (12.1 %) 2 (2.6 %)
2 9 (10.8 %) 1 (1.3 %)
3–5 15 (18.1 %) 0
≥ 6 29 (34.9 %) 1 (1.3 %)
Median time (range) from first dose to first episode of neutropenia
onset, days
Any grade 20.0 (13–757) 49.5 (15–113)
Grade ≥3 28.0 (14–757) 225.0 (225–225)
Grade 4 16.0 (14–246) –
Total number of episodes of neutropenia in the study
All Grades 472 16
Grade ≥3 265 4
Grade 4 11 0
Median duration (range) of neutropenia by episode, days
Grade ≥3 8 (2–58) 30 (27–31)
Grade 4 7 (3–16) –
Dose reductions, dose interruptions,
or cycle delays due to any grade
neutropenia, n (%)a
43 (51.8 %) –
Permanent discontinuation from the
study due to Grade 3–4 neutropenia,
n (%)a
5 (6.0 %) 0
All Grades neutropenia with overlapping all Grades infections, n (%)b
Yes 23 (36.5 %) 0
No 40 (63.5 %) 4 (100.0 %)
All Grades neutropenia with overlapping Grade 3–4 infections, n (%)b
Yes 1 (1.6 %) 0
No 62 (98.4 %) 4 (100.0 %)
Grade 3–4 neutropenia with overlapping all Grades infections, n (%)c
Yes 13 (28.2 %) 0
No 33 (71.7 %) 1 (100.0 %)
Table 4 Neutropenia clinical patterns in the overall safety
population (as treated population) of the PALOMA-1/TRIO-18
trial (Continued)
Grade 3–4 neutropenia with overlapping Grade 3–4 infections, n (%)c
Yes 0 0
No 46 (100.0 %) 1 (100.0 %)
*Neutropenia included preferred terms “neutropenia” and “neutrophil count
decreased” (MeDRA 16.1 coding dictionary)
‡The number of patients who had at least one on-study assessment for absolute
neutrophil count was 82 in the palbociclib plus letrozole arm and 77 in the
letrozole arm
aPercentages are based on the number of patients in each arm (n) of the
study: 83 in the palbociclib plus letrozole arm, 77 in the letrozole arm
bPercentages are based on the number of patients with all Grades
neutropenia: 63 in the palbociclib plus letrozole arm, 4 in the letrozole arm
cPercentages are based on the number of patients with Grade 3–4
neutropenia: 46 in the palbociclib plus letrozole arm, 1 in the letrozole arm
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Discussion
Hormone receptor-positive (HR+) breast cancer remains
the most common sub-type of breast cancer. Historic-
ally, the most important therapeutic intervention in the
management of patients with HR+ breast cancer has
been the use of anti-estrogen therapy, including tamoxi-
fen, aromatase inhibitors, and fulvestrant. Advanced
breast cancer remains incurable, although with currently
available therapies median survival is in the order of 3–4
years [12–14]. The PALOMA-1/TRIO-18 data and the
regulatory approval of palbociclib represent the first novel
non-endocrine therapy to improve PFS in the front-line
setting of postmenopausal women with ER+/HER2–
advanced breast cancer. While confirmation of this
finding is pending the results of the PALOMA-2/
TRIO-22 study which is a randomized, double-blind
study of palbociclib and letrozole versus placebo and
letrozole, results from the double-blind, placebo-con-
trolled PALOMA-3 study, evaluating palbociclib and ful-
vestrant versus fulvestrant in a hormone-refractory
population confirm the important role of CDK 4/6 inhib-
ition in ER+/HER2– breast cancer. At this time, survival
data from both studies are not mature, but the significant
improvement in PFS of over 10 months in PALOMA-1/
TRIO-18 is clinically meaningful. It is also interesting to
note that the FIRST study, an open label, randomized,
phase II study comparing fulvestrant versus anastrozole in
a front-line, aromatase inhibitor-naive, ER+ population,
demonstrated an improvement of 10 months in time to
progression with fulvestrant (23.4 months for fulvestrant
versus 13.1 months with anastrozole) [15] that ultimately
resulted in an improvement in overall survival [12].
In the current study, we explored the clinical benefit
and safety profile of palbociclib and letrozole in various
sub-groups from the PALOMA-1/TRIO-18 trial, on the
basis of both patient and tumor characteristics. When
the subgroups were analyzed on the basis of age
(<65 years and ≥65 years), there was a consistent benefit
from the addition of palbociclib regardless of age. These
observations are important given that age-related dispar-
ities have been reported for breast cancer outcomes [16].
Furthermore, the incidence of Grade 3/4 adverse events,
the rate of dose reductions, and the rate of discontinua-
tions were similar in the two age groups.
Fig. 3 a Frequency of neutropenia by grade during the first six cycles of treatment in the palbociclib plus letrozole arm of the study. b Frequency of
Grade 3–4 neutropenia and all Grade infections during the first six cycles of treatment in the palbociclib plus letrozole arm of the study
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PALOMA-1/TRIO-18 was a front-line treatment study
for advanced breast cancer, but about half of the patients
had prior systemic therapy in the neoadjuvant/adjuvant
setting. The prior systemic therapy received included
both chemotherapy and anti-hormone approaches such
as non-steroidal aromatase inhibitors, steroidal aroma-
tase inhibitors, and tamoxifen. Consistent with our un-
derstanding of drug resistance, the largest benefit with
palbociclib plus letrozole was seen in those patients
that had never received any prior adjuvant therapy
(HR = 0.341, 95 % CI 0.194–0.599; p = 0.00004). How-
ever, even in those patients that received prior sys-
temic therapy, the benefit of treatment was clinically
meaningful (HR = 0.539, 95 % CI 0.302–0.962; p = 0.0169).
Importantly, in those patients that had had prior endo-
crine therapy, the HR was 0.46 (95 % CI 0.222–0.956;
p = 0.0165), supporting our hypothesis that CDK 4/6
inhibition with palbociclib can overcome resistance to
endocrine therapy [2].
In regard to tumor characteristics, we evaluated both
histologic features and anatomic features. While the ma-
jority of invasive breast cancers are ductal in origin, ap-
proximately 10–15 % are lobular. As expected, the
majority of patients in the PALOMA-1 trial had ductal
carcinoma. In general, it is felt that lobular carcinomas
have a better prognosis than ductal carcinomas, are
more sensitive to endocrine therapy, and do not respond
as well to systemic chemotherapy [17]. With these fac-
tors in mind, we explored whether there was a differen-
tial effect seen with the addition of palbociclib in these
two histologies. When comparing the letrozole arms of
the two subgroups, the ductal carcinoma subgroup had
a better PFS than the lobular carcinoma subgroup
(11.1 months versus 4.8 months). This observation
clearly needs to be interpreted with caution given that
there were only 19 patients in the letrozole arm of the
lobular carcinoma subgroup and other clinical factors
were not accounted for; for example, more patients with
lobular carcinoma received adjuvant systemic therapy
versus the ductal group. Nevertheless, both groups ap-
pear to have benefited from the addition of palbociclib,
with a HR of 0.393 (95 % CI 0.239–0.647; p = 0.00007)
in the ductal group and 0.626 (95 % CI 0.282–1.391;
p = 0.123) in the lobular group. The p value of 0.123 in
the lobular group likely reflects the small sample size.
Whether or not this difference in degree of benefit is
significant will need to be established in larger studies.
Another relevant baseline prognostic factor we evalu-
ated was anatomic stage of the disease. While virtually
all of the patients had Stage IV disease, there was a mix-
ture of those that had visceral disease versus bone-only
or other sites of disease, such as soft tissue or lymph
node metastases. The HR values for these groups
(visceral disease, bone-only, other sites) were 0.547
(95 % CI 0.317–0.944; p = 0.0137), 0.294 (95 % CI, 0.092–
0.945; p = 0.0148), and 0.402 (95 % CI, 0.200–0.808;
p = 0.0040), respectively. While the degree of benefit
mimics the prognosis for these groups, even in the
worst prognosis patient group (i.e., those with visceral
disease) there was a 45 % decrease in the risk of progres-
sion with palbociclib. In addition, the clinical benefit rate
in this group, while less than the other two groups, was
still over 75 %, confirming that the combination is an ap-
propriate option for women with visceral disease. This is
particularly relevant given that this group of patients is
often considered for front-line chemotherapy over endo-
crine therapy.
Finally, the therapeutic benefit of any new agent needs
to be weighed against its side effects profile. As previously
reported [3], the most common side effects with the com-
bination therapy were neutropenia, leukopenia, and fa-
tigue. Palbociclib is dosed using a 3-week on, 1-week off
regimen to manage the neutropenia/leukopenia side ef-
fect. While the high incidence of Grade 3/4 events in the
neutropenia/leukopenia categories is cause for concern,
importantly these events were not associated with serious
infections. This observation was also made in the larger,
double-blind, placebo-controlled PALOMA-3 study [5].
The current US Prescribing Information for Palbociclib
(Ibrance®) [18] recommends checking the absolute neutro-
phil count on day 1 and day 14 of the first two cycles of
therapy. This monitoring schedule was chosen considering
that the onset of neutropenia occurred early during treat-
ment, with median time to any grade, Grade ≥3, and
Grade 4 neutropenia being 20 days, 28 days, and 16 days,
respectively. The study data demonstrate that there is no
cumulative toxicity with regard to neutropenia; instead, its
incidence decreases over time.
For a newly diagnosed patient with ER+/HER2–
advanced breast cancer, the treating physician is
faced with the decision of treating with endocrine therapy
or chemotherapy. This decision is affected by factors such
as menopausal status, ECOG performance status, sites of
disease, and type and length of time from prior adjuvant
therapy. Based on the data from PALOMA-1/TRIO-18,
palbociclib received accelerated approval from the US
FDA for use in these patients. The role of CDK 4/6 inhib-
ition in ER+/HER2– breast cancer has now been further
validated in the larger, PALOMA-3 study. The findings
presented here confirm the consistent benefit of pal-
bociclib and letrozole in several relevant clinical sub-
groups, including patients of older age, patients with
both lobular and ductal carcinoma, and patients with
various disease sites and prior adjuvant therapy. The
PALOMA-1/TRIO-18 study was the first study to demon-
strate a significant improvement in PFS with a novel agent
in the first-line treatment of advanced ER+/HER2–
breast cancer. These findings now await confirmation
Finn et al. Breast Cancer Research  (2016) 18:67 Page 12 of 14
in the larger, phase III, double-blind, placebo-controlled
PALOMA-2/TRIO-22 study which has completed enroll-
ment and is awaiting analyses based on accruing events
(NCT01740427).
Conclusion
We performed an expanded analysis of the efficacy (PFS
and CBR) as well as the safety of palbociclib plus letro-
zole in clinically relevant subgroups from the PALOMA-
1/TRIO-18 trial. The degree of benefit in both median
PFS and the CBR rate observed as a result of the
addition of palbociclib to letrozole was consistent in
nearly all subgroups analyzed and was consistent with
that seen in the overall study population. The safety pro-
file of the combination treatment in all subgroups was
comparable to that in the overall safety population of
the study. The frequency of Grade 3–4 neutropenia in
the overall safety population of the study decreased over
time. Neutropenia was not associated with serious infec-
tions or infectious complications.
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